Cytokinetics Sets June Fireside Chats, Highlights Positive ACACIA-HCM Topline Results
CYTK•Cytokinetics will host fireside chats on June 3 at the Jefferies Healthcare Conference and June 8 at the Goldman Sachs Healthcare Conference, with live webcasts available. It announced positive topline results from its Phase 3 ACACIA-HCM trial and will present full data and engage FDA discussions.
1. Conference Participation
Cytokinetics management will participate in two investor conferences in June: a fireside chat at the Jefferies Healthcare Conference on June 3 at 8:10 AM ET in New York and at the Goldman Sachs Healthcare Conference on June 8 at 9:20 AM ET in Miami Beach, with live webcasts and archived replays on its website for 90 days.
2. Pipeline Progress
The company noted positive topline results from its Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy and plans to present full data at an upcoming medical meeting and discuss these results with the U.S. Food and Drug Administration. Cytokinetics also continues to develop cardiac myosin activator omecamtiv mecarbil and inhibitor ulacamten while advancing its approved MYQORZO® treatment in major markets.
